Marina Protopopova
Overview
Explore the profile of Marina Protopopova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
2098
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomas J, Yurkovetskiy A, Yin M, Bodyak N, Tang S, Protopopova M, et al.
Mol Cancer Ther
. 2024 Feb;
23(4):541-551.
PMID: 38354416
Although microtubule inhibitors (MTI) remain a therapeutically valuable payload option for antibody-drug conjugates (ADC), some cancers do not respond to MTI-based ADCs. Efforts to fill this therapeutic gap have led...
2.
Duvall J, Thomas J, Bukhalid R, Catcott K, Bentley K, Collins S, et al.
J Med Chem
. 2023 Jul;
66(15):10715-10733.
PMID: 37486969
While STING agonists have proven to be effective preclinically as anti-tumor agents, these promising results have yet to be translated in the clinic. A STING agonist antibody-drug conjugate (ADC) could...
3.
Thomas J, Yurkovetskiy A, Yin M, Bodyak N, Gumerov D, Tang S, et al.
Bioorg Med Chem Lett
. 2022 Jul;
72:128876.
PMID: 35788036
Pyrrolobenzodiazepine (PBD) dimers are well-known highly potent antibody drug conjugate (ADC) payloads. The corresponding PBD monomers, in contrast, have received much less attention from the ADC community. We prepared several...
4.
Yurkovetskiy A, Bodyak N, Yin M, Thomas J, Clardy S, Conlon P, et al.
Mol Cancer Ther
. 2021 Mar;
20(5):885-895.
PMID: 33722857
After significant effort over the last 30 years, antibody-drug conjugates (ADC) have recently gained momentum as a therapeutic modality, and nine ADCs have been approved by the FDA to date,...
5.
Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos K, Fox G, et al.
Am J Respir Crit Care Med
. 2018 Oct;
199(5):564-571.
PMID: 30335466
No abstract available.
6.
Molina J, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al.
Nat Med
. 2018 Jun;
24(7):1036-1046.
PMID: 29892070
Metabolic reprograming is an emerging hallmark of tumor biology and an actively pursued opportunity in discovery of oncology drugs. Extensive efforts have focused on therapeutic targeting of glycolysis, whereas drugging...
7.
Moore 2nd J, van Opstal E, Kolling G, Shin J, Bogatcheva E, Nikonenko B, et al.
J Antimicrob Chemother
. 2016 Feb;
71(5):1300-6.
PMID: 26832756
Objectives: Clostridium difficile infection (CDI) is a primary cause of antibiotic-associated diarrhoeal illness. Current therapies are insufficient as relapse rates following antibiotic treatment range from 25% for initial treatment to...
8.
Benito J, Ramirez M, Millward N, Velez J, Harutyunyan K, Lu H, et al.
Clin Cancer Res
. 2015 Nov;
22(7):1687-98.
PMID: 26603259
Purpose: To characterize the prevalence of hypoxia in the leukemic bone marrow, its association with metabolic and transcriptional changes in the leukemic blasts and the utility of hypoxia-activated prodrug TH-302...
9.
Cho B, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, et al.
Blood
. 2015 Jun;
126(2):222-32.
PMID: 26031918
Targeting the stromal cell-derived factor 1α (SDF-1α)/C-X-C chemokine receptor type 4 (CXCR4) axis has been shown to be a promising therapeutic approach to overcome chemoresistance in acute myeloid leukemia (AML)....
10.
Nikonenko B, Reddy V, Bogatcheva E, Protopopova M, Einck L, Nacy C
Antimicrob Agents Chemother
. 2013 Oct;
58(1):587-9.
PMID: 24145521
A phospholipid-based nanoemulsion formulation of SQ641 (SQ641-NE) was active against intracellular Mycobacterium tuberculosis in J774A.1 mouse macrophages, although SQ641 by itself was not. Intravenous (i.v.) SQ641-NE was cleared from circulation...